On March 21, 2022 RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, reported that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics (Press release, RNAGene, MAR 21, 2022, View Source [SID1234610504]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform from RNAGENE.
Unlike the existing antibody treatments, in which antibodies are artificially produced from external cell lines, mRNA-based therapies involve administration of mRNA in patients so that patients’ own cells can produce the encoded therapeutic antibody.
"The Company entered this agreement because this partnership gives us an extraordinary opportunity to expand our development strategy and discover new possibilities in the mRNA therapeutic area," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Through this collaboration, both parties will explore new potentials between the two platforms and develop a new therapeutic approach to help patients with unmet medical needs."
"One of the key strengths of mRNA therapy is that it is simple and cost-effective because there is no need to produce antibodies externally in a facility," said Dr. Woo Gil Lee, CEO of RNAGENE. "We are delighted to have PharmAbcine, one of the leading antibody-based therapeutic companies, as a partner for this collaborative research, and we are confident that our advanced mRNA technology platform will help create alternative therapeutic options in oncology field."